医疗器械开发商MAGENTIQ EYE获得A轮融资，推动人工智能胃肠病学的未来发展-动脉网

MAGENTIQ EYE Secures Series A Investment Led by aMoon to Drive the Future of AI-Powered Gastroenterology

CISION 等信源发布 2025-07-30 19:12



可切换为仅中文







Funding will support commercialization in the

资金将支持商业化进程

USA

美国

and

和

Europe

欧洲

as well as continued development of MAGENTIQ COLO's advanced AI capabilities.

以及继续开发MAGENTIQ COLO的先进人工智能能力。

HAIFA, Israel

海法，以色列

，

July 30, 2025

2025年7月30日

/PRNewswire/ -- MAGENTIQ EYE LTD., a leading innovator in AI-powered gastroenterology decision-support software, today announced the successful completion of its Series A funding round.

/PRNewswire/ -- MAGENTIQ EYE LTD.，一家在人工智能驱动的胃肠病学决策支持软件领域领先的创新公司，今天宣布成功完成了其A轮融资。

MAGENTIQ EYE's FDA- and CE-approved software,

MAGENTIQ EYE的FDA和CE批准的软件，

MAGENTIQ-COLO™,

磁量色™，

enhances polyp detection and analysis capabilities during colonoscopies, significantly improving adenoma detection rates. MAGENTIQ-COLO also offers real-time insights, and its CE-approved version includes polyp-size category and type estimation, and advanced AI-generated reports.

增强结肠镜检查期间的息肉检测和分析能力，显著提高腺瘤检出率。MAGENTIQ-COLO 还提供实时洞察，其 CE 认证版本包括息肉大小分类和类型估计，以及高级人工智能生成的报告。

The round was led by aMoon,

本轮融资由 aMoon 领投，

Israel's

以色列的

largest HealthTech dedicated investment fund, joined by internal investors Norgine Ventures BV (

最大的健康科技专用投资基金，由内部投资者Norgine Ventures BV加入（

Netherlands

荷兰

), Nina Capital (EU &

），Nina Capital（欧盟及

USA

美国

) and Namarel Ventures SL (

）和Namarel Ventures SL（

Spain

西班牙

), Nova Capital (

），新星资本（

Italy

意大利

), and private investors Sake Bosch and Roon Doornink (

)，以及私人投资者萨克·博世和鲁恩·多林克（

USA

美国

). In conjunction with aMoon's investment, partner

). 在与aMoon的投资联合中，合作伙伴

Roy Wiesner

罗伊·威斯纳

will join the board of directors of

将加入董事会

MAGENTIQ EYE

磁量智能

, bringing strategic insight, global perspective, and deep experience in building successful health tech companies.

，带来战略洞察、全球视角以及构建成功的健康科技公司的深厚经验。

'This investment round marks a major milestone for MAGENTIQ EYE. We are thrilled to welcome aMoon and

“本轮投资标志着MAGENTIQ EYE的一个重要里程碑。我们非常高兴欢迎aMoon和

Roy Wiesner

罗伊·威斯纳

to our journey,' said

‘开始我们的旅程，’他说

Dror Zur

德罗尔·祖尔

, Ph.D., founder and CEO of MAGENTIQ EYE. 'With aMoon's support, we will accelerate innovation and market access, meeting the growing demand reflected in our robust pipeline of trial and purchase requests across the U.S. and

，MAGENTIQ EYE的创始人兼首席执行官。“在aMoon的支持下，我们将加快创新和市场准入，满足我们在美国各地强劲的试用和购买请求管道中反映出的不断增长的需求，

Europe

欧洲

, and bring our advanced diagnostic tools to more physicians and patients around the world.'

，并将我们先进的诊断工具带给全世界更多的医生和患者。'

'We are proud to partner with MAGENTIQ EYE, a company leading the charge in AI-powered colonoscopy,' said Wiesner. 'MAGENTIQ's solution stands out as the most accurate in the market, with the broadest set of features, cost-effective scalability, and platform flexibility across GI and laparoscopic applications.

“我们很自豪能与MAGENTIQ EYE合作，这是一家在AI驱动的结肠镜检查领域处于领先地位的公司，”威斯纳说。“MAGENTIQ的解决方案在市场上独树一帜，具有最广泛的特性、高性价比的可扩展性以及在胃肠和腹腔镜应用中的平台灵活性。”

We're also encouraged by the strong early commercial traction and the growing interest from major strategic players looking to collaborate. This investment reflects aMoon's commitment to backing transformative health tech solutions that can dramatically improve patient outcomes worldwide.'.

我们对强劲的早期商业吸引力以及主要战略参与者表现出的日益增长的合作兴趣感到鼓舞。这项投资反映了aMoon致力于支持能够显著改善全球患者预后的变革性健康技术解决方案。

The company is in clinical trials for diagnostic tools targeting specialized diseases in the lower and upper gastrointestinal tract, such as ulcerative colitis, early dysplasia in Barrett's esophagus, and gastric intestinal metaplasia, and is developing automated quality indicators for GI procedures.

公司正在进行针对下消化道和上消化道特殊疾病（如溃疡性结肠炎、巴雷特食管早期异型增生和胃肠道化生）的诊断工具的临床试验，并正在开发胃肠手术的自动化质量指标。

Proceeds from the funding round will support the continued development and expansion of these capabilities, in addition to driving commercial growth in the .

这笔融资的收益将支持这些能力的持续开发和扩展，此外还将推动商业化增长。

USA

美国

，

Europe

欧洲

and globally through direct sales and MAGENTIQ EYE's existing and new partnerships with industry leaders.

通过直接销售和MAGENTIQ EYE与行业领导者现有的及新的合作伙伴关系，在全球范围内开展业务。

About MAGENTIQ-EYE Ltd.

关于MAGENTIQ-EYE有限公司。

Founded in 2014, MAGENTIQ-EYE provides a groundbreaking AI-aided colonoscopy solution that offers one of the best performances known today. With worldwide recognition from the gastroenterology community, and dozens of procedures performed every day with the assistance of MAGENTIQ-COLO™, we are setting the new standard of colonoscopy and saving more and more lives. .

MAGENTIQ-EYE 成立于2014年，提供了一种突破性的 AI 辅助结肠镜解决方案，其性能堪称当今最佳之一。凭借全球胃肠病学界的广泛认可，以及每天在 MAGENTIQ-COLO™ 的辅助下完成的数十例手术，我们正在树立结肠镜检查的新标准，挽救越来越多的生命。

www.magentiq.com

About aMoon

关于aMoon

aMoon

月亮

is a global Healthtech & Life Sciences VC fund headquartered in

是一家总部位于全球的健康科技和生命科学风险投资基金

Israel

以色列

with

$1.3B

13亿美元

AUM. We partner with entrepreneurs harnessing groundbreaking science and technology to transform healthcare and help people live better, healthier lives. Backed by a team of scientists, physicians, and entrepreneurs, and a global network of investors and industry leaders, we connect portfolio companies to global tech, finance, and medical research hubs.

资产管理。我们与利用开创性科学技术的企业家合作，以改变医疗保健并帮助人们过上更好、更健康的生活。我们得到了科学家、医生和企业家团队以及全球投资者和行业领袖网络的支持，将投资组合公司与全球技术、金融和医学研究枢纽连接起来。

Our Velocity Fund invests from venture formation through Series A, while our Growth Fund supports later-stage companies in growth, pre-IPO, or pivotal clinical rounds..

我们的 Velocity 基金从风险投资成立到 A 轮进行投资，而我们的 Growth 基金则支持成长阶段、上市前或关键临床阶段的后期公司。

Media contact:

媒体联系人：

Kim Mohr

金·莫尔

Amendola Communications on behalf of MAGENTIQ EYE

代表MAGENTIQ EYE的阿门多拉通信公司

kmohr@acmarketingpr.com

SOURCE MAGENTIQ-EYE LTD.

来源：MAGENTIQ-EYE有限公司

WANT YOUR COMPANY'S NEWS

希望贵公司的新闻